KHCC International Advisory Board was established in March 2003 and is comprised of renowned scientific advisors who guide KHCC on specific research and clinical initiatives. They include:
Dr. Karen Antman Deputy Director for Translational and Clinical Science, National Cancer Institute, Maryland, USA
Dr. Jean Pierre Armand Chairman of European Organization for Research and Treatment of Cancer, Brussels, Belgium
Dr. Otis Brawley Associate Director, Emory University Cancer Center, Georgia, USA
Dr. Bruce Chabner Clinical Director, Massachusetts General Hospital Cancer Center, Harvard Medical School. Massachusetts, USA
Dr. William Dalton CEO and Director, H. Lee Moffitt Cancer Center and Research Institute Florida, USA
Dr. Phillip DiSaia Chairman, Gynecologic Oncology Group, USA
Dr. Michael Friedman President and CEO, City of Hope, California, USA
Dr. Anne Kolker Executive Director, The National Ovarian Cancer Coalition, USA
Dr. Lawrence S. Lessin Medical Director, Washington Hospital Center, Washington D.C., USA
Dr. James Lynch Chief Administrative Officer, Fox Chase Cancer Center, Philadelphia, USA
Dr. Herbert Pinedo Director, Free University Cancer Center, Amsterdam, The Netherlands
Dr. Raul Ribeiro Director, Outreach Program, St. Jude Children's Research Hospital, Tennessee, USA
Dr. Ulrik Ringborg Professor of Oncology at the Karolinska Institute, Stockholm, Sweden
Dr. Steven Rosen Director, Northwestern University Cancer Center, Illinois, USA
Dr. Yousef Rustum Deputy Director, Roswell Park Cancer Center, New York, USA
Dr. John Seffrin President and CEO, American Cancer Society, USA
Mr. Raj Shah Chairman and CEO, Capital Technology Information Services, Maryland, USA
Dr. Daniel Von Hoff Director, Arizona Cancer Center, Arizona, USA
Dr. Robert Wittes Physician - in-Chief, Memorial Sloan Kettering Cancer Center, New York, USA.